X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
atrial fibrillation (243) 243
index medicus (217) 217
warfarin (200) 200
non-vitamin k antagonist oral anticoagulants (191) 191
humans (176) 176
anticoagulants (139) 139
cardiac & cardiovascular systems (127) 127
dabigatran (126) 126
stroke (117) 117
rivaroxaban (99) 99
administration, oral (98) 98
atrial fibrillation - drug therapy (87) 87
aged (80) 80
anticoagulants - administration & dosage (80) 80
anticoagulants - therapeutic use (77) 77
female (76) 76
male (76) 76
apixaban (73) 73
stroke prevention (73) 73
anticoagulants - adverse effects (70) 70
anticoagulation (68) 68
risk (67) 67
stroke - prevention & control (59) 59
vitamin k antagonists (58) 58
non-vitamin k oral anticoagulants (56) 56
atrial fibrillation - complications (55) 55
edoxaban (55) 55
risk factors (55) 55
non-vitamin k antagonist oral anticoagulant (54) 54
oral anticoagulants (51) 51
venous thromboembolism (51) 51
hemorrhage - chemically induced (50) 50
middle aged (48) 48
peripheral vascular disease (48) 48
safety (48) 48
treatment outcome (48) 48
antithrombotic therapy (47) 47
bleeding (47) 47
management (46) 46
aged, 80 and over (45) 45
therapy (45) 45
cardiology (44) 44
thromboembolism (44) 44
prevention (43) 43
medicine & public health (41) 41
vitamin k - antagonists & inhibitors (41) 41
hematology (40) 40
pharmacology & pharmacy (39) 39
cardiac arrhythmia (37) 37
efficacy (37) 37
medicine, general & internal (36) 36
atrial-fibrillation (35) 35
stroke - etiology (35) 35
retrospective studies (31) 31
vitamin k (31) 31
internal medicine (29) 29
analysis (28) 28
catheter ablation (28) 28
intracranial hemorrhage (28) 28
review (28) 28
atrial fibrillation - diagnosis (26) 26
metaanalysis (26) 26
vitamin-k antagonists (26) 26
patients (25) 25
thromboembolism - prevention & control (25) 25
care and treatment (24) 24
drug therapy (24) 24
fibrillation (24) 24
outcomes (24) 24
mortality (23) 23
oral anticoagulation (23) 23
dabigatran - therapeutic use (22) 22
rivaroxaban - therapeutic use (22) 22
warfarin - adverse effects (22) 22
direct oral anticoagulants (21) 21
factor xa inhibitor (21) 21
guidelines (21) 21
cardiovascular (20) 20
nonvalvular atrial-fibrillation (20) 20
thrombosis (20) 20
dabigatran - adverse effects (19) 19
dabigatran etexilate (19) 19
dosage and administration (19) 19
noacs (19) 19
warfarin - administration & dosage (19) 19
cardioversion (18) 18
vitamin k antagonist (18) 18
warfarin - therapeutic use (18) 18
adherence (17) 17
atrial fibrillation - epidemiology (17) 17
atrial fibrillation - therapy (17) 17
hemorrhage (17) 17
time factors (17) 17
abridged index medicus (16) 16
aspirin (16) 16
clinical neurology (16) 16
clinical trials (16) 16
follow-up studies (16) 16
medical research (16) 16
medicine, experimental (16) 16
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (373) 373
German (17) 17
Japanese (15) 15
Russian (4) 4
French (2) 2
Hungarian (2) 2
Spanish (2) 2
Korean (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Thrombosis and Haemostasis, ISSN 0340-6245, 2015, Volume 113, Issue 6, pp. 1113 - 1126
Summary Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used in the prevention and treatment of venous thromboembolism and in the... 
Review Article | Bleeding management | Bleeding profiles | Reversal agent | Non-vitamin K oral anticoagulant | Real-world data | DABIGATRAN ANTICOAGULATION | STROKE PREVENTION | HEMOSTATIC AGENTS | real-world data | reversal agent | RANDOMIZED EVALUATION | bleeding management | non-vitamin K oral anticoagulant | INTRACRANIAL HEMORRHAGE | ACTIVATED FACTOR-VII | PROTHROMBIN COMPLEX CONCENTRATE | PERIPHERAL VASCULAR DISEASE | NONVALVULAR ATRIAL-FIBRILLATION | HEMATOLOGY | ACUTE VENOUS THROMBOEMBOLISM | ELDERLY-PATIENTS | Perioperative Care | Recombinant Proteins - therapeutic use | Meta-Analysis as Topic | Postoperative Hemorrhage - prevention & control | Humans | Clinical Protocols | Warfarin - adverse effects | Postoperative Hemorrhage - chemically induced | Vulnerable Populations | Antithrombins - pharmacokinetics | Thrombophilia - etiology | Neoplasms - complications | Clinical Trials, Phase III as Topic | Blood Transfusion | Drug Design | Retrospective Studies | Thrombophilia - drug therapy | Antidotes - chemistry | Risk Assessment | Hemorrhage - therapy | Antithrombins - therapeutic use | Atrial Fibrillation - complications | Factor Xa Inhibitors - pharmacokinetics | Randomized Controlled Trials as Topic | Factor Xa Inhibitors - therapeutic use | Intracranial Hemorrhages - therapy | Hemostatic Techniques | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Intracranial Hemorrhages - chemically induced | Blood Coagulation Factors - therapeutic use | Kidney Failure, Chronic - complications | Aged | Disease Management | Hemorrhage - chemically induced | Antidotes - therapeutic use | Renal Dialysis
Journal Article
European Heart Journal, ISSN 0195-668X, 04/2018, Volume 39, Issue 16, pp. 1394 - 1403
Abstract Aims To evaluate the effect of telemonitoring on adherence to non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF)... 
Adherence | Telemonitoring | Atrial fibrillation | Non-Vitamin K antagonist oral anticoagulants | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | MANAGEMENT | PERSISTENCE | RISK | REGIMENS | STROKE | IMPACT | THERAPY | Non-vitamin K antagonist oral anticoagulants | MEDICATION ADHERENCE
Journal Article
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2016, Volume 129, Issue 10, pp. 1117 - 1123.e2
Journal Article
Chest, ISSN 0012-3692, 02/2019, Volume 155, Issue 2, pp. 354 - 363
Chronic anticoagulation is recommended in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Non-vitamin K antagonist oral... 
atrial fibrillation | hypertrophic cardiomyopathy | non-vitamin K antagonist oral anticoagulants | ischemic stroke
Journal Article
Journal of Cardiovascular Pharmacology, ISSN 0160-2446, 09/2018, Volume 72, Issue 3, pp. 153 - 160
AIMS:Thrombocytopenia was one of the exclusion criteria in randomized trials in which non–vitamin K antagonist oral anticoagulants (NOACs) were tested. The... 
Thrombocytopenia | Non–Vitamin K antagonist oral anticoagulants | Stroke | Atrial fibrillation | Bleeding | DIAGNOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | non-vitamin K antagonist oral anticoagulants | bleeding | MANAGEMENT | thrombocytopenia | SAFETY | GUIDELINES | APIXABAN | stroke | atrial fibrillation | DABIGATRAN | THERAPY | WARFARIN | DAILY-CARE PATIENTS | PULMONARY-EMBOLISM | PHARMACOLOGY & PHARMACY | Dabigatran - adverse effects | Dabigatran - administration & dosage | Prospective Studies | Age Factors | Humans | Middle Aged | Male | Antithrombins - administration & dosage | Case-Control Studies | Rivaroxaban - administration & dosage | Thrombocytopenia - complications | Factor Xa Inhibitors - administration & dosage | Pyridones - administration & dosage | Rivaroxaban - adverse effects | Time Factors | Aged, 80 and over | Female | Atrial Fibrillation - diagnosis | Pyrazoles - adverse effects | Stroke - prevention & control | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | Treatment Outcome | Pyrazoles - administration & dosage | Stroke - etiology | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Thrombocytopenia - diagnosis | Aged | Hemorrhage - chemically induced | Pyridones - adverse effects | Anticoagulants (Medicine) | Dosage and administration | Safety and security measures | Drug therapy
Journal Article
European Heart Journal, ISSN 0195-668X, 05/2019, Volume 40, Issue 19, pp. 1531 - 1537
Although a recent expert consensus statement has recommended periprocedural uninterrupted (UI) non-vitamin K antagonist oral anticoagulants (NOACs) during... 
Non-vitamin K antagonist oral anticoagulant | Atrial fibrillation | Catheter ablation | Bleeding
Journal Article
Journal of the American Medical Directors Association, ISSN 1525-8610, 08/2019, Volume 20, Issue 8, pp. 984 - 987
Factors that influence decision of non–vitamin K antagonist oral anticoagulants (NOACs) use among older atrial fibrillation (AF) patients in long-term care... 
atrial fibrillation | elderly | Non–vitamin K antagonist oral anticoagulants | Non-vitamin K antagonist oral | anticoagulants | RISK | GERIATRICS & GERONTOLOGY | Medical records | Anticoagulants (Medicine) | Atrial fibrillation | Analysis | Long-term care of the sick | Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 08/2018, Volume 138, Issue 6, pp. 627 - 633
Catheter ablation has gained a prominent role in the management of atrial fibrillation (AF), with recent data providing positive evidence on hard outcomes,... 
heparin | non-vitamin K antagonist oral anticoagulant | activated clotting time | atrial fibrillation catheter ablation | monitoring | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Nursing, ISSN 0962-1067, 05/2019, Volume 28, Issue 9-10, pp. 1839 - 1846
Journal Article